Verici Dx gains Olink Certified Service Provider status to expand proteomics offering

Health Pharma & Biotech Written by: Ephrem Joseph 08:42 Tue 11 Aug 2026 --> Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ephrem Joseph Ephrem began his journalistic journey at Proactive in June 2021. With a strong academic background in Information Technology, his expertise particularly lies in the field of Cyber Security, Management Information Systems and Computer Forensics. Before joining Proactive, Ephrem worked as a researcher and lecturer at a number of leading universities, including the University of Portsmouth's Institute of Criminal Justice Studies, the University of Winchester’s Institute of Policing, and Jain... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Verici Dx PLC ( AIM:VRCI ) View Price & Profile Verici Dx gains Olink Certified Service Provider status to expand proteomics offering Published: 08:42 11 Aug 2026 BST Verici Dx PLC (AIM:VRCI) has become an Olink Certified Service Provider, allowing the transplant diagnostics company to offer Olink-based proteomics assay services from its CAP-certified and CLIA-accredited laboratory. The certification, part of Thermo Fisher’s Life Sciences Solutions network, enables Verici Dx to support biomarker discovery, algorithm development, validation, clinical trials and diagnostic applications for both external clients and its own development pipeline. Proteomics is the large-scale study of proteins - what proteins are present in cells, tissues or blood, how much of each protein there is, and how they change in disease. Expands multi-omics capabilities The Olink platform will strengthen Verici's ability to analyse large proteomic datasets and identify biomarkers and disease signatures across thousands of proteins and patient samples. The company combines proteomics with existing expertise in genomics, transcriptomics and bioinformatics, while operating within a CAP, CLIA and ISO-compliant quality framework designed to support the translation of biomarker discoveries into clinical-grade assays. Certification requires providers to complete specialist training, annual concordance testing and re-certification. Early pharmaceutical application Verici Dx has already applied the capability in a collaboration with a major pharmaceutical company involving samples from a GLP-1 clinical trial. The project used a custom proteomic panel to assess biomarker responses in patient samples, with the resulting data contributing to ongoing scientific analysis and submissions. Chief operating officer Patti Connolly said the certification reflected the company’s ability to combine laboratory processing with bioinformatics and clinical development expertise. Continue reading